Skip to content

Study · Animal study (in vivo) · rat · 2017

3 results

Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats.

Sever'yanova LА, Dolgintsev ME

Bulletin of experimental biology and medicine27 Nov 2017Cited by 2 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats in a foot-shock aggression model, Gly-His-Lys showed an analgesic effect.

    In plain wordsIn rats in a foot-shock model, Gly-His-Lys reduced pain.

    Outcome
    DecreasePain
    Study

    ratsn: not reported in source

    Foot-shock aggression model
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    5, 15, 50 and 150 μg/kg · intraperitonealAs given in this study (rats).

    Source sentences

    Summary
    Analgesic and antiaggresiogenic effects of the peptide were demonstrated.
    2 context sentences
    Summary · context
    We studied the effect of Gly-His -Lys tripeptide administered intraperitoneally in doses of 5, 15, 50 and 150 μg/kg on pain-induced aggressive-defensive behavior.
    Summary · context
    A foot-shock model of aggression in rats grouped in pairs in an electrified chamber was used.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats in a foot-shock aggression model, Gly-His-Lys showed an antiaggressive effect.

    In plain wordsIn rats in a foot-shock model, Gly-His-Lys reduced aggressive behavior.

    Outcome
    DecreaseAggressive-defensive behavior
    Study

    ratsn: not reported in source

    Foot-shock aggression model
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    5, 15, 50 and 150 μg/kg · intraperitonealAs given in this study (rats).

    Source sentences

    Summary
    Analgesic and antiaggresiogenic effects of the peptide were demonstrated.
    2 context sentences
    Summary · context
    We studied the effect of Gly-His -Lys tripeptide administered intraperitoneally in doses of 5, 15, 50 and 150 μg/kg on pain-induced aggressive-defensive behavior.
    Summary · context
    A foot-shock model of aggression in rats grouped in pairs in an electrified chamber was used.

Studies that did not test the peptide alone1

In this study, GHK (glycyl-L-histidyl-L-lysine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHK (glycyl-L-histidyl-L-lysine).

  1. 03AnimalNot a test of GHK (glycyl-L-histidyl-L-lysine) aloneAnimal study (in vivo)Mechanism

    In rats, effects after L-lysine administration near its equimolar content in Gly-His-Lys supported a key role for the lysine residue.

    In plain wordsIn rats, L-lysine produced similar effects, which supported its key role in Gly-His-Lys activity.

    Outcome
    Not applicableL-lysine contribution
    Study

    ratsn: not reported in source

    Foot-shock aggression model
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    It was found the L-lysine residue plays the key role in these effects, because they were observed under the influence of L-lysine administration in doses close to its equimolar content in the studied tripeptide.
    2 context sentences
    Summary · context
    We studied the effect of Gly-His -Lys tripeptide administered intraperitoneally in doses of 5, 15, 50 and 150 μg/kg on pain-induced aggressive-defensive behavior.
    Summary · context
    A foot-shock model of aggression in rats grouped in pairs in an electrified chamber was used.

    In this study, GHK (glycyl-L-histidyl-L-lysine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK (glycyl-L-histidyl-L-lysine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.